Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002664296 | SCV003525318 | uncertain significance | Biotinidase deficiency | 2022-08-19 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This missense change has been observed in individual(s) with clinical features of biotinidase deficiency (PMID: 9654207, 26361991). This variant is present in population databases (rs397514419, gnomAD 0.006%). This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 451 of the BTD protein (p.Gly451Asp). |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV003324083 | SCV004029300 | uncertain significance | not specified | 2023-07-28 | criteria provided, single submitter | clinical testing | Variant summary: BTD c.1292G>A (p.Gly431Asp) results in a non-conservative amino acid change located in the C-terminal domain (IPR043957) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251428 control chromosomes (i.e., 2 heterozygotes; gnomAD v2.1 Exomes dataset). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1292G>A has been reported in the literature in individuals affected with Biotinidase Deficiency (e.g., Swango_1998, Lindau-Shepard_2012, Gannavarapu_2015). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 26361991, 27625817, 9654207). One submitter has reported clinical-significance assessments for this variant to ClinVar after 2014 and has classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. |